Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02946151
Other study ID # 2016IL01
Secondary ID CIV-16-05-015704
Status Completed
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date February 11, 2019

Study information

Verified date May 2019
Source Zealand University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a two-phase study, which aims to explore the uses of a novel electrode type in detecting epileptic seizures. The electrode is designed for subcutaneous implantation with long-term monitoring in mind.


Description:

The problem of unrecognized seizures is common for certain types of epilepsy. Electroencephalography (EEG) is an excellent method for seizure identification and recognition, but until now, it has not been feasible to perform EEG recordings for more than a few days outside a hospital or laboratory. A novel device has been developed, which might remedy that. The device is a EEG-electrode for subcutaneous implantation connected to an external data storage device.

The investigators in this study hypothesize that this device might be a useful tool for ultra-long-term epilepsy monitoring. The study aims to investigate that. While the device might be used to diagnose epilepsy, it is more likely to be a good seizure counting tool and that is what the study aims to determine.

Subjects include patients with mesial temporal lobe epilepsy and high seizure frequency. These will have the device implanted. Study phase 1 is a proof of concept to determine whether the device is actually able to detect epileptic seizures. This will take place during admission and be performed as simultaneous recordings with ordinary scalp EEG and the investigational device. Study phase 2 is a home monitoring to prove that devices actually provides clinically useful information regarding seizures in an outpatient setting.

The study requires 9 visits from each subject over the course of 4-6 months. The investigational device will be explanted after approximately 75 days of wear.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date February 11, 2019
Est. primary completion date January 23, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

1. Semiology of some seizures compatible with mesial temporal lobe involvement.

2. Paraclinical findings supporting mesial temporal seizure focus. Such proof may consist of:

- previous EEG recording interpreted as compatible with mesial temporal involvement OR

- radiological findings demonstrating pathology in the mesial temporal area (CT, MRI, FDG-PET or SPECT).

3. Age 18-90.

4. Current seizure frequency (fulfilling criteria 1) of more than one per week to be eligible to EMU admission or 1 per month for direct enrollment to home monitoring (by own account).

5. Available for the duration of the study (6 months from screening).

Exclusion Criteria:

1. Known disorder of hemostasis.

2. Daily or frequent (more than 2 days per week) treatment with any drugs of the following types:

- antiplatelets

- anticoagulants

- chemotherapeutics

- non-steroid anti-inflammatory drugs (NSAID)

- omega 3 fatty acids (fish oil)

3. Skeletal deformities or damage at the proposed implantation site to an extent that impedes correct electrode placement.

4. Scheduled facial or cranial surgery within 6 months from enrollment.

5. Active deep brain stimulation device.

6. Presence of implanted ICD pacemaker, cochlear implant or other active implants.

7. Planned transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) in the duration of the study.

8. Presence of any implanted device at the proposed site of implantation.

9. Known allergy towards any material that is part of the investigational device.

10. Females of childbearing potential who are pregnant, intend to become pregnant, or are not using adequate contraceptive methods throughout the study.

11. Performing extreme sport, including scuba diving (snorkel diving is allowed), parachute jumping or martial arts.

12. Scheduled MRI within 5 months from enrollment.

13. Work involving operation of MRI-scanner.

14. Operating hand held transceivers for communication (e.g. within the police, medical, fire, air traffic control, marine or military).

15. Working at broadcast stations for television or FM/DAB radio.

16. Known or suspected abuse of alcohol defined as estimated consumption beyond that, which is recommended by the DHA or any other neuro-active substances.

17. Active vagus nerve stimulator.

18. Skin disorders near the proposed implantation site, including infection.

19. Contraindications against the local anesthetic drug used during im- and explantation.

20. Diabetes of any kind.

21. Psychiatric disorders including:

- schizophrenia

- bipolar affective disorder

- emotionally unstable personality disorder

- schizoaffective disorder

- schizotypal disorder

- autism

22. Severely abnormal paraclinical findings or vital signs:

- S-creatinine = 3 times upper reference value

- ALAT, alkaline phosphatase or bilirubin= 3 times upper reference value

- APTT > 50 seconds

- thrombocyte count < 50 or >1000 x 10^9/l

- INR = 1,6

- HgBA1C > 55 mmol/mol

- Any ECG finding requiring immediate referral to a cardiologist as assessed by the investigator

- pulse <40 bpm or >120 bpm or suspicion of atrial fibrillation by auscultation

- temperature >38 ÂșC

- respiration rate >30 pr. minute

- systolic blood pressure < 80 mmHg or >220 mmHg and diastolic blood pressure <50 mmHg or >120 mmHg

- any other clinical or paraclinical finding suggesting known or unknown illness or disorder requiring immediate treatment as assessed by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
UNEEG implantable EEG electrode and data storage device
The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.

Locations

Country Name City State
Denmark Zealand University hospital Roskilde

Sponsors (3)

Lead Sponsor Collaborator
Zealand University Hospital Technical University of Denmark, UNEEG Medical A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seizure comparison Qualitative comparison of patient-recorded seizures and EEGgraphical seizures 24 months
Primary Adverse events Descriptive account of device related adverse events 24 months
Primary Compliance Descriptive account of compliance in use of the investigational device 24 months
See also
  Status Clinical Trial Phase
Completed NCT06269822 - Autonomic Dysfunction in Temporal Lobe Epilepsy and SUDEP
Completed NCT05159609 - Closed Loop Auditory Stimulus in Sleep and epilepsY N/A
Not yet recruiting NCT02590419 - Application of Diffusion Tensor Imaging and Tractography in Epilepsy Surgery N/A
Completed NCT00595699 - Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy Phase 4
Recruiting NCT06466681 - Changes in Attentional Control After a Focal Seizure.
Recruiting NCT05609084 - Intensive Preoperative Speech Rehabilitation in Drug-Resistant Temporal Epilepsy N/A
Completed NCT00344877 - Electrical Brain Stimulation to Reduce Epileptic Seizures N/A
Not yet recruiting NCT05794295 - Sleep Architecture & Intrinsic Oscillatory and Network Connectivity in Cognition and Executive Dysfunction in TLE N/A
Recruiting NCT03643471 - Advanced Magnetic Resonance Imaging in Temporal Lobe Epilepsy
Terminated NCT00717431 - A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy Phase 3
Completed NCT02844465 - Stereotactic Laser Ablation for Temporal Lobe Epilepsy N/A
Recruiting NCT05179083 - Exercise for Brain Regeneration in Epilepsy Phase 1
Recruiting NCT05019404 - Minimally Invasive Surgical Epilepsy Trial for Temporal Lobe Epilepsy N/A